DepYmed
Private Company
Total funding raised: $40M
Overview
DepYmed is a clinical-stage biotech leveraging a proprietary platform to develop selective inhibitors of protein tyrosine phosphatase 1B (PTP1B) and copper chelators. The company is advancing two orally bioavailable small molecules into clinical trials, with its lead asset, DPM-1003 for Rett Syndrome, having recently received FDA clearance to initiate a Phase 1 trial. With a focus on rare diseases and oncology, DepYmed is backed by venture capital and led by a team with deep expertise in drug development and phosphatase biology.
Technology Platform
Platform for developing selective small molecule inhibitors of protein tyrosine phosphatase 1B (PTP1B) and novel copper chelating agents.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
In Rett Syndrome, competition includes gene therapy and other symptomatic approaches, but few direct PTP1B inhibitors. In Wilson Disease, DepYmed's novel chelator would compete against existing standard-of-care drugs and other next-generation agents in development. The oncology PTP1B inhibitor space is emerging with limited direct competitors.